GIL 2026 | Frost & Sullivan awards Frost & Sullivan China China Annual Company Award for 2026 Global Autoimmunity and Inflammation Small Molecule New Drug by Lingke Pharmaceutical

Lingke Pharmaceutical was registered in Hangzhou, Zhejiang at the end of 2017. It is an innovative biotech company focusing on autoimmune and inflammatory diseases, dedicated to developing small moleculeFIC(First-in-Class) and BIC (Best-in-Class) drug research and development. By developing innovative therapies, it meets unmet clinical needs, aiming to benefit global patients through differentiated innovative therapies. So far, Lingke Pharmaceutical has developed several independently developed first-class clinical new drugs and has conducted multiple clinical trials globally independently or in collaboration with international partners.

The company is firmly advancing the clinical development and commercialization of its core products. It has received over 1 billion RMB in financing, including from Eli Asia Fund, Junan Capital, and Dacheng Capital. The core product LNK01001 (Zepixitin), an oral second-generation highly selective JAK1 inhibitor, has completedatopic dermatitisPhase III clinical trial. The Phase III clinical trial for rheumatoid arthritis is about to be completed, and the Phase III clinical trial for ankylosing spondylitis is ongoing. The disclosed top-line clinical data show that the Phase 24-week placebo-controlled study of Zepixitin for rheumatoid arthritis andatopic dermatitisPhase 16-week placebo-controlled study of atopic dermatitis have perfectly achieved all major and key secondary efficacy endpoints, showing statistically significant improvements compared to placebo and demonstrating good safety. For the atopic dermatitis indication, the New Drug Application (NDA) was submitted in April 2026 and accepted, with approval expected in 2027. The rheumatoid arthritis indication is expected to submit the NDA in the second half of 2026. In 2022, the company reached a commercialization agreement with Sinovac Pharmaceutical for LNK01001, with the latter responsible for the domestic promotion of the two indications of rheumatoid arthritis and ankylosing spondylitis.

The company's core products form a clear dual-wheel drive strategy: LNK01001, an oral selective JAK1 inhibitor, focuses on systemic autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, atopic dermatitis, and vitiligo), while LNK01004, an external soft pan-JAK inhibitor, focuses on the local skin inflammation area (moderate to severe atopic dermatitis, vitiligo, etc.). LNK01004 is a potential first-in-world tissue-restricted external soft pan-JAK inhibitor. Its design achieves extremely low systemic exposure and restricted skin distribution of the drug. Clinical data show that its systemic exposure is significantly lower than that of approved external JAK inhibitors. The key product LNK01006 is a penetrative central nervous system modulatory TYK2 inhibitor, targeting central nervous system-related diseases. It has been licensed to Bleecker Bio, a new company established through cooperation with Lingke Pharmaceutical by American Formation Bio. Currently, LNK01006 (BLKR201) is undergoing Phase I clinical trials in the US. Additionally, the company has established the innovative LynkNova^®protein degradation platform. Based on this platform, several innovative candidate drugs such as LNK009 (STAT6 PROTAC), LNK011 (VAV1 MGD), LNK013 (IRAK4 PROTAC), and LNK014 (NEK7 MGD) have been developed. The company has established a global intellectual property protection system, continuously strengthening the technical barrier.

Lingke Pharmaceutical continues to win wide recognition from the industry and capital markets due to solid clinical data and differentiated pipeline layout. The company is actively expanding its global layout. It has reached an exclusive development and licensing agreement for LNK01006 with Bleecker Bio, receiving payments including a down payment, milestone payments, and rights to development, registration, and commercialization milestones, totaling over 605 million US dollars. As of 2026, the company has two core products and seven additional clinical or pre-clinical candidate drugs. Looking to the future, Lingke Pharmaceutical is accelerating the commercialization process of its core products, continuously expanding diverse application scenarios from autoimmune diseases to central nervous system inflammatory diseases, and pushing Chinese small molecule innovative drugs to the forefront of the world.